AlbertCLockhartMD
Oncology • Charleston, SCGastrointestinal Cancer, Hematologic Oncology
Associate Professor, Internal Medicine, Washington University in St. Louis School of Medicine
Dr. Lockhart is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
171 Ashley Ave
Charleston, SC 29425Phone+1 843-792-1414Fax+1 305-243-9161
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 1997 - 2000
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1993 - 1996
University of Texas Southwestern Medical SchoolClass of 1993
Certifications & Licensure
SC State Medical License 2021 - 2025
FL State Medical License 2017 - 2023
MO State Medical License 2008 - 2018
TN State Medical License 2001 - 2010
NC State Medical License 1999 - 2003
TX State Medical License 1995 - 2001
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012
Clinical Trials
- PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy Start of enrollment: 2011 Jul 01
- Collection and Storage of Tissue and Blood Samples From Patients With Cancer Start of enrollment: 2015 May 19
Publications & Presentations
PubMed
- Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate Cancer.Ling Zhang, Clara I Troccoli, Beatriz Mateo-Victoriano, Laura Misiara Lincheta, Erin Jackson
Cancer Research. 2025-01-02 - Phase I study of allogeneic monocyte-derived inflammatory dendritic cells in combination with pembrolizumab.Jared Weiss, Douglas Laux, David Bajor, Albert C Lockhart, John Hamm
Future Science OA. 2024-12-01 - 45 citationsDefactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study.Andrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, Rama Suresh, Albert C Lockhart
Clinical Cancer Research. 2022-12-15
Press Mentions
US Patent for Cannabis-Derived Drug to Treat Eye DiseasesMay 22nd, 2019
Lowe’s Flavocure Secures US Patent for Ganja Eye DrugMay 17th, 2019
$10.4 Million Awarded for Pancreatic Cancer ResearchAugust 15th, 2016
Grant Support
- Medical University of South Carolina NCORP Minority/Underserved Community SiteMEDICAL UNIVERSITY OF SOUTH CAROLINA2014–2025
- Pharmacogenomically Selected Treatment For Gastric And Gastroesophageal JunctionNational Cancer Institute2008
- Genetic Polymorphisms Affecting Chemotherapy DispositionNational Cancer Institute2008
- Genetic Polymorphisms Affecting Chemotherapy DispositionNational Cancer Institute2004–2008
- Pharmacogenomically Selected Treatment For Gastric And Gastroesophageal JunctionNational Cancer Institute2007
- Response To Paclitaxel Related To Genitic Variatins In MDR1National Center For Research Resources2006
- Correlation On The Pharmacokinetics And Toxicity Of CPT-11 With FunctionallyNational Center For Research Resources2005–2006
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
